Publikationen 2012

  • Regulated microRNAs in the CSF of patients with multiple sclerosis: A case control study. Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Decard BF, Gold R. Neurology. 2012; 79(22):2166-2170.

 

  • Low vitamin D and elevated immunoraectivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. Décard BF, von Ahsen N, Grunwald T, Streit F, Stroet A, Niggemeier P, Schottstedt V, Riggert J, Gold R, Chan A. J Neurol Neurosurg Psychiatry. 2012; 83(12):1170-3.

 

  • TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Gregory AP, Dendrou CA, Attfield KE, Haghikia A, Xifara DK, Butter F, Poschmann G, Kaur G, Lambert L, Leach OA, Prömel S, Punwani D, Felce JH, Davis SJ, Gold R, Nielsen FC, Siegel RM, Mann M, Bell JI, McVean G, Fugger L. Nature 2012; 488(7412): 508-11.

 

  • Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A. Neurology 2012, 29;78(22):1736-42.

 

  • Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis. Thöne J, Ellrichmann G, Faustmann PM, Gold R, Haghikia A. Int. Immunopharmacol. 2012, 14(1):9-12

 

  • Potassium channel KIR4.1 as an immune target in multiple sclerosis. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, Tackenberg B, Rothhammer V, Chan A, Gold R, Berthele A, Bennett JL, Korn T, Hemmer B. N Eng J Med. 2012, 367:115-23.

 

  • Failure of natalizumab to prevent relapses in neuromyelitis optica. Kleiter I, Hellwig K, Berthele A, Kümpfel C, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Arch Neurol. 2012; 69(2):239-45.  

 

  • Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germay. Stroet A, Hemmelmann C, Starck M, Zettl U, Dörr J, Paul F, Flachenecker P, Fleischer V, Zipp F, Nückel H, Kieseier BC, Ziegler A, Gold R, Chan A. Ther Adv Neurol Disord. 2012; 5:75-79.

 

  • Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behaviour. Peruga I, Hartwig S, Merkler D, Thöne J, Hovemann B, Juckel G, Gold R, Linker RA. Behav Brain Res. 2012; 229:325-32

  • Monitoring Peripheral Blood CD4+ Intracellular Adenosine Triphosphate Concentration in Patients with Psoriasis Treated with Fumaric Acid Esters. Gambichler T, Scola N, Totterdam S, Höxtermann S, Haghikia A, Faissner S, Kreuter A, Bechara FG, Altmeyer P, Chan A. Acta Derm Venereol. 2012 [Epub ahead of print].

 

  • Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. Ellrichmann G, Thöne J, Lee DH, Rupec RA, Gold R, Linker RA. J Neuroinflammation. 2012; 9(1):15.


  • Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Lee DH, Geyer E, Flach AC, Jung K, Gold R, Flügel A, Linker RA, Lühder F. Acta Neuropathol. 2012;123(2):247-58.


  • Multiple sclerosis: more pieces of the immunological puzzle. Gold R, Montalban X. Lancet Neurol. 2012; 11(1):9-10.
     
  • Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor. Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R. Am J Pathol. 2012;180(1):267-74.